The anti-EGFR monoclonal antibody nimotuzumab achieved a longer survival with a tolerable toxicity when added to gemcitabine (8.7 months vs. 6.1 months), in a recent phase II trial in patients with locally advanced pancreatic cancer [37]. This evidence concerns the gene EGFR and pancreatic neoplasm.